Hemolytic disease of the fetus and newborn: managing the mother, fetus, and newborn
نویسندگان
چکیده
منابع مشابه
Hemolytic disease of the fetus and newborn: managing the mother, fetus, and newborn.
Hemolytic disease of the fetus and newborn (HDFN) affects 3/100 000 to 80/100 000 patients per year. It is due to maternal blood group antibodies that cause fetal red cell destruction and in some cases, marrow suppression. This process leads to fetal anemia, and in severe cases can progress to edema, ascites, heart failure, and death. Infants affected with HDFN can have hyperbilirubinemia in th...
متن کاملHemolytic disease of the fetus and newborn.
KM The primary cause, of course, is maternal antibodies to red blood cells. Their formation usually occurs at delivery, and in the following pregnancy, those antibodies cross through the placenta and can affect the next fetus. When the antibodies attach to the fetal red blood cells, the cells break down and the fetus becomes anemic. In the United States, the 3 antibodies that cause nearly all t...
متن کاملClinical Management of Hemolytic Disease of the Newborn and Fetus
Hemolytic disease of the fetus and newborn (HDFN) is caused by maternal alloantibodies directed against antigens present in fetal red cells. Paternally inherited antigens of the Rh system, which differ to those from the mother, are present on fetal red cells and when the maternal immune system makes contact with a significant number of these cells create an immune response with antibodies again...
متن کاملHaemolytic Disease of the Fetus and Newborn
The antibodies responsible for haemolysis can be naturally occuring (eg, anti-A or anti-B antibodies) or can develop as a result of a sensitising event such as pregnancy or transfusion. The most well recognised is rhesus alloimmunisation (Greek: allo = 'other' or 'different from') which begins with red blood cells from a rhesus-positive fetus crossing the placental barrier during pregnancy and ...
متن کاملOn Fetus and Newborn
Maternal use of certain drugs during pregnancy can result in transient neonatal signs consistent with withdrawal or acute toxicity or cause sustained signs consistent with a lasting drug effect. In addition, hospitalized infants who are treated with opioids or benzodiazepines to provide analgesia or sedation may be at risk for manifesting signs of withdrawal. This statement updates information ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Hematology
سال: 2015
ISSN: 1520-4391,1520-4383
DOI: 10.1182/asheducation-2015.1.146